Cargando…
A phase II open label clinical study of the safety, tolerability and efficacy of ILB(®) for Amyotrophic Lateral Sclerosis
INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is an invariably lethal progressive disease, causing degeneration of neurons and muscle. No current treatment halts or reverses disease advance. This single arm, open label, clinical trial in patients with ALS investigated the safety and tolerability...
Autores principales: | Logan, Ann, Nagy, Zsuzsanna, Barnes, Nicholas M., Belli, Antonio, Di Pietro, Valentina, Tavazzi, Barbara, Lazzarino, Giuseppe, Lazzarino, Giacomo, Bruce, Lars, Persson, Lennart I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132272/ https://www.ncbi.nlm.nih.gov/pubmed/35613082 http://dx.doi.org/10.1371/journal.pone.0267183 |
Ejemplares similares
-
ILB(®) Attenuates Clinical Symptoms and Serum Biomarkers of Oxidative/Nitrosative Stress and Mitochondrial Dysfunction in Patients with Amyotrophic Lateral Sclerosis
por: Lazzarino, Giacomo, et al.
Publicado: (2021) -
Low Molecular Weight Dextran Sulfate (ILB(®)) Administration Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat
por: Lazzarino, Giacomo, et al.
Publicado: (2020) -
The mechanism of action of a novel neuroprotective low molecular weight dextran sulphate: New platform therapy for neurodegenerative diseases like Amyotrophic Lateral Sclerosis
por: Logan, Ann, et al.
Publicado: (2022) -
ILB(®), a Low Molecular Weight Dextran Sulphate, Restores Glutamate Homeostasis, Amino Acid Metabolism and Neurocognitive Functions in a Rat Model of Severe Traumatic Brain Injury
por: Lazzarino, Giacomo, et al.
Publicado: (2022) -
Severity of experimental traumatic brain injury modulates changes in concentrations of cerebral free amino acids
por: Amorini, Angela Maria, et al.
Publicado: (2016)